<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01870440</url>
  </required_header>
  <id_info>
    <org_study_id>NCRVA-2013-Ozurdex-16.2</org_study_id>
    <nct_id>NCT01870440</nct_id>
  </id_info>
  <brief_title>TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema</brief_title>
  <official_title>TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern California Retina Vitreous Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northern California Retina Vitreous Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an intravitreal dexamethasone implant
      (Ozurdex, Allergan) is effective to manage macular edema secondary to non-infectious uveitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uveitis accounts for more than 10% of all cases of severe vision loss in developed countries,
      which makes it possibly the fourth leading cause of blindness in the United States. Cystoid
      macular edema (CME) is the most structural complication of uveitis, resulting in visual
      impairment and blindness. If left untreated or undertreated over a period of years, CME may
      result in permanent photoreceptor damage of the macula and loss of central vision. Further,
      CME may persist despite adequate control of the uveitis, and therefore, adjuvant therapy to
      specifically treat the CME may be required.

      We propose to study whether a sustained steroid delivery system (Ozurdex, Allergan) can treat
      uveitic macular edema. Ozurdex has been proven to be effective for non-infectious posterior
      uveitis; and FDA approved for posterior uveitis. The sustained delivery of the steroid and
      local delivery modality makes it an ideal candidate to manage macular edema in uveitis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity (using Early Treatment Diabetic Retinopathy Study Protocal)</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central Subfoveal Retinal Thickness</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Subfoveal Retinal Thickness</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Macular Edema</condition>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>Ozurdex Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ozurdex Intravitreal Injection (0.7 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex Intravitreal Injection (0.7 mg)</intervention_name>
    <description>Intravitreal Injection</description>
    <arm_group_label>Ozurdex Injection</arm_group_label>
    <other_name>Ozurdex (0.7 mg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Uveitis CME with central subfoveal thickness &gt; 350 microns

          -  non-infectious uveitis

          -  Visual Acuity &gt; 20/32

        Exclusion Criteria:

          -  Visual Acuity worse than 20/200

          -  Moderate or severe glaucoma (as defined as &gt;2 topical ocular medications)

          -  Infectious uveitis

          -  Patients with active or suspected ocular or periocular infections including most viral
             diseases of the cornea and conjunctiva, including active epithelial herpes simplex
             keratitis, vaccinia, varicella, mycobacterial infections, and fungal diseases.

          -  Aphakic eyes with rupture of the posterior lens capsule

          -  Anterior Chamber intraocular Lens and rupture of the posterior lens capsule

          -  Hypersensitivity to any components of the Ozurdex
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Northern California Retina Vitreous Associates</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM; Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011 May;129(5):545-53. doi: 10.1001/archophthalmol.2010.339. Epub 2011 Jan 10.</citation>
    <PMID>21220619</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northern California Retina Vitreous Associates</investigator_affiliation>
    <investigator_full_name>Rahul Khurana, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Uveitis</keyword>
  <keyword>Macular Edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

